Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level

Clin Biochem. 2011 Aug;44(12):975-9. doi: 10.1016/j.clinbiochem.2011.05.005. Epub 2011 May 18.

Abstract

Objectives: Nephrogenic systemic fibrosis is a novel clinical entity encountered in subjects undergoing contrast enhanced magnetic resonance imaging (MRI). The aim of the present study is to evaluate the impact of contrast enhanced MRI exposure on lymphocyte DNA damage and serum levels of visfatin.

Design and methods: Twenty-eight subjects undergoing contrast enhanced hypophysial MRI with omniscan were included in the study. Blood samples were drawn before MRI, after non-contrast MRI and after contrast enhanced MRI from each subject. Lymphocyte DNA damage was analyzed by the alkaline comet assay, whereas serum visfatin level was assessed with enzyme immuno assay.

Results: Both lymphocyte DNA damage and serum visfatin levels were statistically significantly increased in samples withdrawn after contrast enhanced MRI compared to samples withdrawn after non-contrast enhanced MRI and baseline samples (ANOVA p<0.001, for both).

Conclusions: Findings of the present study revealed that the contrast enhanced MRI is associated with increased lymphocyte DNA damage and increased serum visfatin level.

MeSH terms

  • Adult
  • C-Reactive Protein / metabolism
  • Contrast Media / adverse effects*
  • DNA Damage*
  • Female
  • Gadolinium DTPA
  • Humans
  • Lymphocytes / drug effects*
  • Magnetic Resonance Imaging / adverse effects*
  • Male
  • Middle Aged
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Young Adult

Substances

  • Contrast Media
  • gadodiamide
  • C-Reactive Protein
  • Nicotinamide Phosphoribosyltransferase
  • Gadolinium DTPA